Name
AS Remedium Kalamaja Apteek
Registry code
10011111
VAT number
EE100289912
Type
AS - Joint Stock Company
Status
Registered
Foundation date
22.02.1996 (28)
Financial year
01.01-31.12
Capital
25 560.00 €
Activity
47731 - Dispensing chemist in specialised stores
1 524 171 €
5 860 €
0%
1 176 €
(estimate is approximate)
141 621 €
9
Submitted
No tax arrears
4%
2%
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Kariina Stepanova 06.03.1982 (42) | 38% - 9 585.00 EUR | - | Direct ownership | Chairman of the boardShareholder |
| Kaja Stepanova 15.05.1951 (73) | 63% - 15 975.00 EUR | Board member | Direct ownership | Shareholder |
| Ivo Heinmets 25.04.1970 (54) | - | - | - | Board member |
| Ülle Sildmäe 20.10.1966 (58) | - | - | - | Board member |
| 2019 13.08.2020 | 2020 30.06.2021 | 2021 24.05.2022 | 2022 12.06.2023 | 2023 25.06.2024 | |
|---|---|---|---|---|---|
| Total Revenue | 3 325 699 € | 2 054 094 € | 1 410 806 € | 1 783 636 € | 1 524 171 € |
| Net profit (loss) for the period | 19 025 € | 17 734 € | 16 859 € | 26 034 € | 5 860 € |
| Profit Margin | 1% | 1% | 1% | 1% | 0% |
| Current Assets | 519 052 € | 342 498 € | 365 350 € | 298 849 € | 283 810 € |
| Fixed Assets | 97 831 € | 96 193 € | 94 555 € | 92 917 € | 91 279 € |
| Total Assets | 616 883 € | 438 691 € | 459 905 € | 391 766 € | 375 089 € |
| Current Liabilities | 463 749 € | 279 823 € | 300 178 € | 230 005 € | 233 468 € |
| Non Current Liabilities | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - |
| Share Capital | 25 560 € | 25 560 € | 25 560 € | 25 560 € | 25 560 € |
| Equity | 153 134 € | 158 868 € | 159 727 € | 161 761 € | 141 621 € |
| Employees | 9 | 9 | 9 | 9 | 9 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | 454 616.65 € | 27 014.88 € | 17 397.86 € | 8 |
| 2023 Q4 | 402 807.78 € | 22 911.95 € | 16 616.32 € | 8 |
| 2023 Q3 | 441 318.51 € | 21 614.38 € | 16 275.11 € | 8 |
| 2023 Q2 | 344 971.59 € | 22 577.75 € | 17 646.88 € | 7 |
| 2023 Q1 | 364 458.08 € | 21 030.35 € | 16 928.23 € | 9 |
| 2022 Q4 | 465 320.09 € | 28 827.83 € | 19 106.19 € | 9 |
| 2022 Q3 | 454 632.41 € | 25 826.3 € | 17 935.48 € | 9 |
| 2022 Q2 | 451 814.27 € | 26 099.16 € | 17 918.51 € | 9 |
| 2022 Q1 | 464 610.58 € | 22 049.81 € | 18 036.81 € | 9 |
| 2021 Q4 | 464 030.95 € | 28 369.94 € | 19 345.27 € | 9 |
| 2021 Q3 | 305 391.43 € | 23 610.74 € | 19 460.76 € | 9 |
| 2021 Q2 | 334 580.08 € | 13 771.69 € | 9 788.1 € | 9 |
| 2021 Q1 | 325 553.09 € | 27 018.61 € | 18 795.95 € | 9 |
| 2020 Q4 | 469 903.07 € | 24 196.16 € | 19 510.67 € | 10 |
| 2020 Q3 | 480 551.05 € | 24 065.71 € | 19 784.36 € | 10 |
| 2020 Q2 | 493 190.98 € | 23 746.97 € | 18 161.71 € | 10 |
| 2020 Q1 | 716 395.83 € | 27 152.54 € | 21 615.28 € | 10 |
